• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acelyrin Inc (NQ: SLRN )

    4.980 +0.050 (+1.01%)
    Streaming Delayed Price Updated: 11:01 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Acelyrin Inc

    < Previous 1 2 3 4 5 6 Next >
    ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Participate in Upcoming Investor Conferences
    From ACELYRIN, INC.
    Via GlobeNewswire
    SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
    SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
    SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
    SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
    Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
    Via Benzinga
    Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
    Via Benzinga
    ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Leadership Transition
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
    From ACELYRIN, INC.
    Via GlobeNewswire
    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
    From Avalo Therapeutics
    Via GlobeNewswire
    Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
    Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
    Via Benzinga
    ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
    Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
    Via Benzinga
    ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    WHY: NEW YORK, NY - (NewMediaWire) - January 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    WHY: NEW YORK, NY - (NewMediaWire) - January 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.